Views
1287 of 1287 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 TerSera Therapeutics LLCPrivate | 1 asset: 1 approved | Approved assets only | 30 Mar 2027Goserelin · Phase 1 |
TetraLogic PharmaceuticalsTLOG · OTC Pink | 1 asset: 1 Ph 2 | BirinapantPhase 2 · Ovarian Cancer | None on record |
 TherAguixPrivate | 1 asset: 1 Ph 2 | AGuIXPhase 1/2 · Non-Small Cell Lung Cancer | None on record |
 TheracosPrivate | 1 asset: 1 approved | Approved assets only | None on record |
 TheraviaPrivate | 1 asset: 1 approved | Approved assets only | Feb 2028Hydroxyurea (Siklos) · Phase 2 |
 Therini Bio, Inc.Private | 1 asset: 1 Ph 1 | THN391Phase 1 · Alzheimer's Disease | 31 Mar 2027THN391 · Phase 1 |
 Thryv TherapeuticsPrivate | 1 asset: 1 Ph 3 | THRV-1268Phase 2/3 · Heart FailurePartial signal | 30 Jun 2027THRV-1268 · Phase 2/3 |
Tianjin SinoBiotechPrivate | 1 asset: 1 Ph 2 | Human Serum Albumin/interferon alpha2b fusion proteinPhase 1/2 · Chronic Hepatitis B | None on record |
 Tiziana Life Sciences Ltd.TLSA · Nasdaq | 1 asset: 1 Ph 2 | ForalumabPhase 2 · Multiple Sclerosis | 1 Apr 2027Foralumab · Phase 2 |
ToLymph Inc.Private | 1 asset: 1 Ph 2 | SMS001Phase 2 · Non-Small Cell Lung Cancer | 18 Nov 2026SMS001 · Phase 2 |
 TransThera Sciences (Nanjing), Inc.2617 · HKEX | 1 asset: 1 Ph 3 | TinengotinibPhase 3 · HR+/HER2- Metastatic Breast Cancer | Dec 2026Tinengotinib · Phase 3 |
 TransgeneTNG · Euronext Paris | 1 asset: 1 Ph 2 | T101Phase 2 · Chronic Hepatitis B | None on record |
 Treadwell Therapeutics, IncPrivate | 1 asset: 1 Ph 2 | CFI-400945Phase 1/2 · Acute Myeloid LeukemiaWeak signal | None on record |
 Trevi Therapeutics, Inc.TRVI · Nasdaq | 1 asset: 1 Ph 3 | Nalbuphine ERPhase 3 · Prurigo Nodularis | Sep 2027Nalbuphine ER · Phase 2 |
 Triveni BioPrivate | 1 asset: 1 Ph 2 | TRIV-509Phase 2 · Atopic Dermatitis | None on record |
 TrueBinding, Inc.Private | 1 asset: 1 Ph 2 | TB006Phase 2 · Parkinson's Disease | 28 Nov 2026TB006 · Phase 2 |
 TrueLab BiopharmaceuticalPrivate | 1 asset: 1 Ph 1 | TL-003Phase 1 · Ulcerative Colitis | Apr 2027TL-003 · Phase 1 |
 TuHURA BiosciencesHURA · Nasdaq | 1 asset: 1 other | IFx-2.0Merkel Cell Carcinoma | None on record |
 Twinpig Biolab, Inc.Private | 1 asset: 1 Ph 2 | TB511Phase 1/2 · Non-Small Cell Lung Cancer | Mar 2027TB511 · Phase 1/2 |
| 1 asset: 1 Ph 2 | TSN1611Phase 1/2 · Non-Small Cell Lung Cancer | 30 Oct 2026TSN1611 · Phase 1/2 | |
 UNION TherapeuticsPrivate | 1 asset: 1 Ph 2 | orismilastPhase 2 · Atopic DermatitisReliable signal | None on record |
 Umoja BiopharmaPrivate | 1 asset: 1 Ph 1 | UB-VV500Phase 1 · Multiple Myeloma | 31 Dec 2029UB-VV500 · Phase 1 |
 Unicycive TherapeuticsUNCY · Nasdaq | 1 asset: 1 Ph 2 | Oxylanthanum carbonatePhase 2 · Chronic Kidney DiseaseWeak signal | None on record |
 United BioPharmaPrivate | 1 asset: 1 Ph 3 | SemzuvolimabPhase 3 · HIVPartial signal | None on record |
 Upstream BioUPB · Nasdaq | 1 asset: 1 Ph 2 | verekitugPhase 2 · Chronic Obstructive Pulmonary DiseaseReliable signal | Sep 2027verekitug · Phase 2 |
 Usynova Pharmaceuticals Ltd.Private | 1 asset: 1 Ph 1 | UA026Phase 1 · Psoriasis | None on record |
 Uvax BioPrivate | 1 asset: 1 Ph 1 | UVAX-1107Phase 1 · HIV | None on record |
 VM Discovery, Inc.Private | 1 asset: 1 Ph 2 | VMD-102Phase 1/2 · Non-Small Cell Lung Cancer | May 2031VMD-102 · Phase 1/2 |
 VM Oncology, LLCPrivate | 1 asset: 1 Ph 2 | VMD-928Phase 1/2 · Non-Small Cell Lung Cancer | Dec 2027VMD-928 · Phase 1/2 |
 VTBIO Co. Ltd (South Korea)Private | 1 asset: 1 Ph 1 | VT301Phase 1 · Alzheimer's DiseaseWeak signal | None on record |
 Vaccinex, Inc.VCNX · OTC | 1 asset: 1 Ph 2 | PepinemabPhase 1/2 · Alzheimer's DiseasePartial signal | 31 Dec 2028Pepinemab · Phase 1/2 |
 Valo Therapeutics OyPrivate | 1 asset: 1 Ph 1 | PeptiCRAd-1Phase 1 · Non-Small Cell Lung Cancer | 30 Apr 2027PeptiCRAd-1 · Phase 1 |
 Vantive HealthPrivate | 1 asset: 1 approved | Approved assets only | None on record |
 Vasa TherapeuticsPrivate | 1 asset: 1 Ph 1 | Vasa Therapeutics VS-041Phase 1 · Heart Failure | None on record |
 Vascarta Inc.Private | 1 asset: 1 Ph 1 | VAS-101Phase 1 · Sickle Cell Disease | None on record |
 Vaxine Pty LtdPrivate | 1 asset: 1 Ph 2 | HepadvaxPhase 1/2 · Chronic Hepatitis B | 1 Mar 2027Hepadvax · Phase 1/2 |
 VentrixPrivate | 1 asset: 1 Ph 1 | VentriGelPhase 1 · Heart FailureWeak signal | None on record |
 Ventyx Biosciences, Inc.Private | 1 asset: 1 Ph 2 | VTX3232Phase 2 · ObesityPartial signal | None on record |
 Verdiva BioPrivate | 1 asset: 1 Ph 2 | VRB-101Phase 2 · ObesityPartial signal | 30 Nov 2026VRB-101 · Phase 2 |
 Vericel CorporationVCEL · Nasdaq | 1 asset: 1 approved | Approved assets only | Feb 2030autologous cultured chondrocytes on porcine collagen membrane · Phase 3 |
 Vertero TherapeuticsPrivate | 1 asset: 1 Ph 1 | VT-5006Phase 1 · Parkinson's Disease | None on record |
 Vimgreen PharmaceuticalsPrivate | 1 asset: 1 Ph 3 | VG081821ACPhase 2/3 · Parkinson's Disease | 1 Oct 2027VG081821AC · Phase 2/3 |
 Vincentage PharmaPrivate | 1 asset: 1 Ph 3 | VCT220Phase 3 · ObesityReliable signal | 30 Oct 2026VCT220 · Phase 2 |
 Vir BiotechnologyVIR · Nasdaq | 1 asset: 1 Ph 2 | Tobevibart (VIR-3434)Phase 2 · Chronic Hepatitis Delta | None on record |
 ViriomPrivate | 1 asset: 1 approved | Approved assets only | None on record |
Virogenics, Inc.Private | 1 asset: 1 Ph 1 | CMS121Phase 1 · Alzheimer's DiseasePartial signal | None on record |
 Vitrac Therapeutics, LLCPrivate | 1 asset: 1 Ph 2 | VIC-1911Phase 1/2 · Non-Small Cell Lung CancerWeak signal | None on record |
| 1 asset: 1 Ph 2 | EtribnabdionePhase 2 · Atherosclerotic Cardiovascular Disease | Mar 2027Etribnabdione · Phase 2 | |
 Vivace Therapeutics, IncPrivate | 1 asset: 1 Ph 2 | VT3989Phase 1/2 · Non-Small Cell Lung Cancer | 2 Nov 2029VT3989 · Phase 1/2 |
 Volastra Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | VLS-1488Phase 1/2 · Non-Small Cell Lung Cancer | None on record |
 Voronoi, Inc310210 · KOSDAQ | 1 asset: 1 Ph 2 | VRN110755Phase 1/2 · Non-Small Cell Lung Cancer | 1 Jan 2029VRN110755 · Phase 1/2 |
 Vyriad, Inc.Private | 1 asset: 1 Ph 2 | VSV-IFNβ-NISPhase 1/2 · Non-Small Cell Lung Cancer | None on record |
Welichem BiotechPrivate | 1 asset: 1 approved | Approved assets only | Aug 2027Tapinarof · Phase 3 |
| 1 asset: 1 Ph 1 | HWK-007Phase 1 · Non-Small Cell Lung Cancer | Oct 2028HWK-007 · Phase 1 | |
 WinSanTorPrivate | 1 asset: 1 Ph 2 | Pirenzepine (topical)Phase 2 · HIVPartial signal | None on record |
 Windward BioPrivate | 1 asset: 1 Ph 2 | WIN378Phase 2 · Chronic Obstructive Pulmonary DiseasePartial signal | Jul 2027WIN378 · Phase 2 |
| 1 asset: 1 Ph 1 | UWD-00BPhase 1 · Multiple Myeloma | None on record | |
| 1 asset: 1 Ph 3 | QR12000Phase 3 · HypertensionPartial signal | None on record | |
 XYone Therapeutics, IncPrivate | 1 asset: 1 Ph 2 | XYA02Phase 1/2 · Non-Small Cell Lung Cancer | 15 Sep 2029XYA02 · Phase 1/2 |
 Xantho BiotechnologyPrivate | 1 asset: 1 Ph 2 | GM-XANTHOPhase 2 · PsoriasisPartial signal | 31 Dec 2027GM-XANTHO · Phase 2 |
 Xcovery HoldingsPrivate | 1 asset: 1 approved | Approved assets only | None on record |
| 1 asset: 1 Ph 2 | XS-411Phase 1/2 · Parkinson's Disease | 30 Mar 2028XS-411 · Phase 1/2 | |
 Xenon PharmaceuticalsXENE · Nasdaq | 1 asset: 1 Ph 3 | AzetukalnerPhase 3 · Major Depressive DisorderReliable signal | Jan 2027Azetukalner · Phase 3 |
 Xiamen Amoytop Biotech Co., Ltd.688278 · SSE | 1 asset: 1 Ph 1 | ACT201 InjectionPhase 1 · Chronic Hepatitis B | Mar 2027ACT201 Injection · Phase 1 |
 Xilio Development, Inc.XLO · Nasdaq | 1 asset: 1 Ph 2 | XTX501Phase 1/2 · Non-Small Cell Lung Cancer | Nov 2029XTX501 · Phase 1/2 |
| 1 asset: 1 other | Yangxin Dawayimixike Honey PasteAtherosclerotic Cardiovascular Disease | Jul 2028Yangxin Dawayimixike Honey Paste · Approved | |
 Yabao Pharmaceutical GroupPrivate | 1 asset: 1 Ph 1 | Globalagliatin HydrochloridePhase 1 · Type 2 DiabetesPartial signal | None on record |
| 1 asset: 1 Ph 2 | VB19055Phase 2 · Hypertension | Dec 2027VB19055 · Phase 2 | |
 Yiling Pharmaceutical Inc.Private | 1 asset: 1 Ph 1 | FinaminePhase 1 · Parkinson's DiseasePartial signal | None on record |
 Zensun (Shanghai) Sci & TechPrivate | 1 asset: 1 Ph 3 | Recombinant human neuregulin-1 (rhNRG-1)Phase 3 · Heart FailurePartial signal | None on record |
| 1 asset: 1 Ph 1 | CBG002Phase 1 · Multiple Myeloma | 25 Oct 2027CBG002 · Phase 1 | |
 Zhejiang Doer BiologicsPrivate | 1 asset: 1 Ph 3 | DR10624Phase 3 · ObesityPartial signal | Apr 2028DR10624 · Phase 2 |
 Zhejiang Hisun Pharmaceutical600267 · SSE | 1 asset: 1 Ph 3 | HyzetimibePhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record |
 Zhejiang Huahai Pharmaceutical600521 · SSE | 1 asset: 1 Ph 2 | Hypidone (YL-0919)Phase 2 · Major Depressive DisorderPartial signal | None on record |
| 1 asset: 1 Ph 2 | XKH001Phase 2 · Atopic Dermatitis | 1 Apr 2027XKH001 · Phase 1 | |
| 1 asset: 1 Ph 2 | PA1010Phase 1/2 · Chronic Hepatitis B | None on record | |
 Zhiyi PharmaceuticsPrivate | 1 asset: 1 Ph 3 | Live SK08Phase 3 · Ulcerative Colitis | None on record |
Zogenix, Inc.Private | 1 asset: 1 approved | Approved assets only | None on record |
Zomagen BiosciencesPrivate | 1 asset: 1 Ph 2 | VTX3232Phase 2 · ObesityPartial signal | None on record |
 Zumutor Biologics Inc.Private | 1 asset: 1 Ph 1 | ZM008Phase 1 · Non-Small Cell Lung Cancer | Dec 2026ZM008 · Phase 1 |
 iLeukon Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | ILKN421HPhase 2 · Non-Small Cell Lung Cancer | Jun 2029ILKN421H · Phase 2 |
| 1 asset: 1 Ph 1 | iQ-007Phase 1 · Epilepsy | None on record | |
| 1 asset: 1 Ph 2 | NouvNeu001Phase 2 · Parkinson's Disease | Dec 2026NouvNeu001 · Phase 2 | |
 nChroma Bio, Inc.Private | 1 asset: 1 Ph 2 | CRMA-1001Phase 1/2 · Chronic Hepatitis B | 31 Dec 2032CRMA-1001 · Phase 1/2 |
 pharma&Private | 1 asset: 1 approved | Approved assets only | None on record |
 scPharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | None on record |
 selectION TherapeuticsPrivate | 1 asset: 1 Ph 1 | si-544Phase 1 · PsoriasisPartial signal | None on record |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).